HHV8-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified

specific

A large B-cell lymphoma characterized by the presence of a diffuse proliferation of large, atypical HHV8-positive neoplastic lymphocytes. It usually arises in association with HHV8-positive multicentric Castleman disease.

Centers

Active Trials

—

Cancer Funding

Top Centers for HHV8-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified(36)

Ranked by research excellence score (trials · grants · publications). Methodology →

#	Center	Research Tier	Active Trials	Cancer Funding	Score
1	Siteman Cancer CenterSt. Louis, MO NCI Comprehensive Active Research Program	Active Research Program	1	—	65.1
2	Mayo Clinic Comprehensive Cancer CenterRochester, MN NCI Comprehensive Active Research Program	Active Research Program	1	—	65.1
3	The University of Chicago Medicine Comprehensive Cancer CenterChicago, IL NCI Comprehensive Active Research Program	Active Research Program	1	—	65.1
4	Simmons Comprehensive Cancer Center UT Southwestern Medical CenterDallas, TX NCI Comprehensive Active Research Program	Active Research Program	1	—	65.1
5	Laura and Isaac Perlmutter Cancer Center at NYU Langone HealthNew York, NY NCI Comprehensive Active Research Program	Active Research Program	1	—	65.1
6	Moffitt Cancer CenterTampa, FL NCI Comprehensive Active Research Program	Active Research Program	1	—	65.1
7	Roswell Park Comprehensive Cancer CenterBuffalo, NY NCI Comprehensive Active Research Program	Active Research Program	1	—	65.1
8	The University of Arizona Cancer CenterTucson, AZ NCI Comprehensive Active Research Program	Active Research Program	1	—	65.1
9	The University of Kansas Cancer CenterKansas City, KS NCI Comprehensive Active Research Program	Active Research Program	1	—	65.1
10	Dartmouth Cancer CenterLebanon, NH NCI Comprehensive Active Research Program	Active Research Program	1	—	65.1
11	University of Illinois Cancer CenterChicago, IL Active Research Program	Active Research Program	1	—	65.1
12	Cancer Center at IllinoisUrbana, IL Active Research Program	Active Research Program	1	—	65.1
13	Mayo Clinic Comprehensive Cancer Center, FloridaJacksonville, FL Active Research Program	Active Research Program	1	—	65.1
14	Mayo Clinic Comprehensive Cancer Center, ArizonaScottsdale, AZ Active Research Program	Active Research Program	1	—	65.1
15	Memorial Sloan Kettering Cancer CenterNew York, NY NCI Comprehensive		—	—	42.6
16	Stanford Cancer InstitutePalo Alto, CA NCI Comprehensive		—	—	42.6
17	UNC Lineberger Comprehensive Cancer CenterChapel Hill, NC NCI Comprehensive		—	—	42.6
18	Herbert Irving Comprehensive Cancer CenterNew York, NY NCI Comprehensive		—	—	42.6
19	Winship Cancer InstituteAtlanta, GA NCI Comprehensive		—	—	42.6
20	The Ohio State University Comprehensive Cancer Center - James Cancer Hospital & Solove Research InstituteColumbus, OH NCI Comprehensive		—	—	42.6
21	City of Hope Comprehensive Cancer CenterDuarte, CA NCI Comprehensive		—	—	42.6
22	University of Colorado Cancer CenterAurora, CO NCI Comprehensive		—	—	42.6
23	Huntsman Cancer Institute at the University of UtahSalt Lake City, UT NCI Comprehensive		—	—	42.6
24	University of Virginia Cancer CenterCharlottesville, VA NCI Comprehensive		—	—	42.6
25	Sylvester Comprehensive Cancer CenterMiami, FL NCI Clinical		—	—	42.6
26	Cedars-Sinai CancerLos Angeles, CA		—	—	42.6
27	VCU Massey Comprehensive Cancer CenterRichmond, VA NCI Comprehensive		—	—	42.6
28	Cleveland Clinic Cancer CenterCleveland, OH		—	—	42.6
29	Fred & Pamela Buffett Cancer CenterOmaha, NE NCI Clinical		—	—	42.6
30	Rutgers Cancer InstituteNew Brunswick, NJ NCI Comprehensive		—	—	42.6
31	University of Hawai‘i Cancer CenterHonolulu, HI NCI Clinical		—	—	42.6
32	UAMS Winthrop P. Rockefeller Cancer InstituteLittle Rock, AR		—	—	42.6
33	Boston University Cancer CenterBoston, MA		—	—	42.6
34	Georgia Cancer Center, Augusta UniversityAugusta, GA		—	—	42.6
35	Upstate Cancer CenterSyracuse, NY		—	—	42.6
36	Louisiana Cancer Research CenterNew Orleans, LA		—	—	42.6

Research tier badges reflect trial volume, NIH grant funding, and publication impact — not clinical outcomes or patient satisfaction. Learn about our methodology →